Latest Articles

Publication Date
Repurposing ramipril to mitigate EMT-like transition in endometriosis by PI3K/AKT/S6K1 signalling pathway: a study in endometriosis induced rats.

Endometriosis, an atypical benign disorder, may disrupt epithelial-mesenchymal transition (EMT) due to a dysregulated balance between matrix metalloproteinases (MMPs) and their inhibitors. Ramipril, an angiotensin converting enzyme (ACE) inhibitor, is …

Published: Jan. 28, 2026, midnight
HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

Ovarian clear cell carcinoma (CCC) is an aggressive subtype of ovarian cancer that is resistant to conventional chemotherapy, resulting in poor prognosis. CCC develops from endometriosis, which exposes tumor cells …

Published: Jan. 27, 2026, midnight
Endometriosis and the Hallmarks of Cancer.

Endometriosis (EMS) is a non-cancerous invasive condition where tissue resembling the lining of the uterus is found outside of the uterine cavity. Endometriotic lesions have been found in nearly every …

Published: Dec. 23, 2025, midnight
Hypoxia-inducible factor-1 alpha expression in endometriosis: A retrospective observational case-control study of ovarian cyst capsules and endometrial tissue samples.

BackgroundThis study aimed to compare the expression patterns of hypoxia-inducible factor-1α in ovarian cyst capsules and endometrial tissue samples from patients with and without endometriosis to evaluate its potential as …

Published: Oct. 23, 2025, midnight
Expression profiles of E-cadherin and N-cadherin in endometriosis and other gynecological diseases towards targeted treatment: a systematic review.

This systematic review aimed to summarize all available data and evaluate the roles of E-cadherin, N-cadherin, associated molecules, and signaling pathways in the pathogenesis of endometriosis. The search was conducted …

Published: Aug. 21, 2025, midnight
A cRGD-modified liposome for targeted delivery of artesunate to inhibit angiogenesis in endometriosis.

Currently, hormonal therapy for endometriosis faces challenges in achieving a balance between treatment and preserving the chance of pregnancy. Therefore, the development of non-hormonal therapy holds significant clinical importance. Angiogenesis …

Published: Jan. 20, 2025, midnight
The PKM2/HIF-1α Axis is Involved in the Pathogenesis of Endometriosis via TGF-β1 under Endometrial Polyps.

Endometriosis patients exhibit a cancer-like glycolytic phenotype. The pyruvate kinase M2 (PKM2)/hypoxia-inducible factor-1 alpha (HIF-1α) axis plays important roles in glycolysis-related diseases, but its role in patients with endometrial polyps …

Published: Dec. 31, 2024, midnight
[Mechanism of Luoshi Neiyi Formula in treatment of SF-1 on endometriosis by improving hypoxia].

This study investigated the effect of Luoshi Neiyi Formula(LSNYF) on hypoxia-inducible factor-1α(HIF-1α) and steroidogenic factor 1(SF-1) in endometriosis(EMs), aiming to explore the mechanism of Luoshi Neiyi Formula in treating EMs. …

Published: Dec. 21, 2024, midnight
Endometriosis development in relation to hypoxia: a murine model study.

Endometriosis, due to its ambiguous symptoms, still remains one of the most difficult female diseases to treat, with an average diagnosis time of 7-9 years. The changing level of hypoxia …

Published: Oct. 30, 2024, midnight
Inhibiting NTRK2 signaling causes endometriotic lesion regression.

Endometriosis is a common gynecological disease in reproductive-age women. Although the hormone-dependent therapy is the first line treatment for endometriosis, it is not a curative regimen and associated with severe …

Published: Oct. 14, 2024, 1:21 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!